This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mayne Pharma Group Past Earnings Performance

Past criteria checks 0/6

Key information

-20.0%

Earnings growth rate

-18.3%

EPS growth rate

Pharmaceuticals Industry Growth	31.2%
Revenue growth rate	-7.6%
Return on equity	-49.2%
Net Margin	-62.0%
Next Earnings Update	23 Feb 2023

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Mayne Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CHIA:MYXDA Revenue, expenses and earnings (AUD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 22	425	-263	229	15
31 Mar 22	407	-170	209	17
31 Dec 21	388	-78	190	19
30 Sep 21	395	-143	181	20
30 Jun 21	401	-208	173	22
31 Mar 21	420	-232	180	22
31 Dec 20	439	-256	187	22
30 Sep 20	448	-174	194	24
30 Jun 20	457	-93	200	25
31 Mar 20	467	-196	210	26
31 Dec 19	478	-300	220	27
30 Sep 19	502	-290	231	28
30 Jun 19	525	-279	241	29
31 Mar 19	543	-118	230	27
31 Dec 18	561	43	219	25
30 Sep 18	546	-46	208	20
30 Jun 18	530	-134	197	15
31 Mar 18	526	-146	196	12
31 Dec 17	521	-158	194	8
30 Sep 17	547	-35	192	8
30 Jun 17	573	89	190	8
31 Mar 17	504	90	173	8
31 Dec 16	435	91	156	8
30 Sep 16	351	64	136	7
30 Jun 16	267	37	115	7
31 Mar 16	238	30	105	7

Quality Earnings: MYXDA is currently unprofitable.

Growing Profit Margin: MYXDA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MYXDA is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.

Accelerating Growth: Unable to compare MYXDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYXDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).

Return on Equity

High ROE: MYXDA has a negative Return on Equity (-49.17%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/01/25 07:57
End of Day Share Price	2023/01/24 00:00
Earnings	2022/06/30
Annual Earnings	2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	APP Securities Pty Ltd.
Russell Wright	Barclay Pearce Capital Pty Limited
John Hester	Bell Potter